Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Livespo Navax – World’s first spore probiotics in nasal spray form triumphs in ongoing clinical trials tackling influenza-related respiratory inflammation

LiveSpo

HANOI, VIETNAM - Media OutReach - 30 November 2023 - A recent publication in the Scientific Reports - Nature journal has once again highlighted the clinical trials of LiveSpo Navax spore probiotic spray. These trials focus on its effectiveness against respiratory tract inflammation from the influenza virus. This news marks a significant milestone for the Vietnamese medical sector, especially in setting a trend in global research and application of spore probiotics for respiratory well-being. Using a nasal spray with Bacillus probiotics in treating influenza patients has significantly reduced the total treatment time by up to 60 per cent (from five days for the control group to just two days for the spore probiotics spray group). Additionally, it increased treatment efficacy by 58 per cent, aiding in the complete recovery from symptoms such as runny nose, fever, sneezing, cough, rapid heartbeat, and rapid breathing. The decline in clinical symptoms corresponds with a drop in both viral and bacterial counts, notably decreasing by approximately 400 and 1,000 times on the second treatment day compared to the initial day of hospitalisation. The clinical trials confirm that the nasal spray containing Bacillus probiotics reduces treatment duration, lowering the chances of bacterial infection or severe respiratory tract complications. This not only helps cut treatment costs but also reduces antibiotic consumption for infections, fostering improved patient health. This positive signal is crucial for the medical community as it contributes to easing the burden on hospitals during disease outbreaks. Furthermore, the clinical trials indicate that the Bacillus probiotics, when formulated as a spray, offer superior effectiveness through interaction with the mucosal immune system of the nasal cavity. This means that the spore probiotics nasal spray not only supports the treatment of influenza-infected patients but also aids in treating respiratory tract inflammation caused by other viruses such as RSV, adenovirus, rhinovirus, coronavirus, etc. Regular use of Bacillus probiotics spray proves beneficial in enhancing the respiratory barrier, thereby boosting the effectiveness of virus-prevention vaccines. Probiotics, also known as a type of medicinal probiotics, serve as an effective solution in alleviating symptoms of respiratory diseases. In a previous study published in the Scientific Reports - Nature journal in July 2022, LiveSpo Navax supported the treatment of respiratory syncytial virus (RSV) in children. It significantly reduced the treatment time by more than one day and lowered the RSV concentration by over 600 times, surpassing the effectiveness of using physiological saline. This scientific research ranked among the top 100 downloaded microbiology articles in 2022 in the Nature Journal, demonstrating the widespread interest from scientists and readers worldwide and contributing significant values to the community. The two internationally validated clinical studies have confirmed that the LiveSpo Navax nasal spray, containing Bacillus probiotics, has demonstrated no side effects, guaranteeing complete safety for children. All patients using LiveSpo Navax in conjunction with standard treatment medications showed no signs of local bacterial infection or any digestive issues like vomiting, diarrhoea, or other abnormal symptoms. Therefore, in the future, this product will be fully suitable for inclusion in treatment plans for patients infected with respiratory viruses or bacteria. Dr. Nguyen Hoa Anh, Director of the Spore Probiotics Research Center shared: "We are proud to offer an effective support solution for patients with respiratory infections caused by viruses, bacteria, or acute inflammation. Moving forward, we will continue to research, develop, and bring the LiveSpo Navax product to consumers in Viet Nam and globally." With groundbreaking technology in spore probiotics - medicinal probiotics, LiveSpo Pharma aims to build a future free of antibiotics for everyone. Dang Quoc Hung, CEO of LiveSpo Pharma, stated: "At LiveSpo, we always strive to deliver the best products to our customers and the community. With the expertise of our scientific team, who have achieved notable research milestones in microbiology domestically and internationally, we are confident in developing and manufacturing effective and convenient spore probiotic products without side effects. This effort contributes to reducing antibiotic use and minimising antibiotic resistance in Viet Nam and the world. This is also LiveSpo's mission for development." As confirmed by the two successful publications in the prestigious Scientific Reports - Nature journal, LiveSpo has asserted its breakthrough in the products resulting from the company's extensive research and development efforts. LiveSpo takes pride in introducing Viet Nam's spore probiotics technology to the markets of developed countries which spearhead global medical advancements. This groundwork sets the stage for the future growth of Vietnamese enterprises, emphasising the expansion into global markets and the international promotion of Vietnamese brands and products. With a focus on product development, LiveSpo aims to create value for the community. The company's successful development of the Bacillus probiotics spray, which effectively aids respiratory disease treatment and minimises the risk of severe inflammation and prolonged antibiotic use, is helping pave the way toward a future less reliant on antibiotics. With its nature as a type of medical probiotic, LiveSpo products will help strengthen the natural immune barrier for the body when used over an extended period, thereby contributing to a community immune system if widely applied. This serves as a natural shield, protecting the community from diseases caused by viruses and bacteria. About LiveSpo Pharma LiveSpo is an R&D, manufacturing, and distribution brand of Spobiotics (probiotics in spore form) for digestive and respiratory health, leading in breakthrough technology, rapid effectiveness, and convenience, aiming for "A Future Without Antibiotics". Hotline: 1800.088808 Website: livespo.com Contact Details Livespo Media Contact (Mr) Chu Minh Dac +84 98 459 95 96 dac.cm@livespo.com Company Website https://livespo.com/

November 30, 2023 08:55 AM Eastern Standard Time

Image

The Cultivated B Launches Next-Gen Bioreactor Remote Monitoring and Control Software

The Cultivated B

The Cultivated B (TCB) today announced the availability of its groundbreaking bioreactor control software, enabling a real-time, application-based, personalized user interface with added remote accessibility for its AUXO V® bioreactors. The software, now accessible via the control tower or remotely via phone- and web-based software, marks a significant leap forward in the cultivated meat industry, offering unparalleled convenience, flexibility and efficiency for expert and non-expert users to manage bioprocesses. TCB’s commercially available bioreactor, AUXO V, can be monitored and controlled by anyone, from any location with only a few days of training. “Our new bioreactor user interface embodies TCB’s commitment to innovation and flexibility for users, helping to scale the cultivated meat industry. Now, extremely complex processes can be run with the ease of a household device,” said The Cultivated B CEO Dr. Hamid Noori. “This technology is more than just a product; it's another proof point in our vision of a world where cultivated meat is easily accessible. In order to industrialize sustainable protein production, it is essential that a larger workforce can be trained on new processes, rather than building operations around experts only. We believe that by simplifying the monitoring and control of the production process and making it accessible anywhere at any time, we can significantly accelerate the pace at which cultivated meat reaches mass adoption.” The new bioreactor control software is tailored to meet the diverse needs of user groups with different experience levels, including existing as well as new user groups. Remote monitoring benefits include: Increased flexibility – Choose between direct or remote control of bioprocesses Sustained monitoring – 24/7 availability allows rapid intervention in the event of irregularities Optimized allocation of workforce – Eliminate the need for users to remain onsite by automating processes The next-generation monitoring is not just a technological advancement but also a strategic response to the global shortage of know-how and skilled workers needed to scale the cultivated meat industry. TCB equips the AUXO V bioreactor with an innovative user interface featuring three levels of detail: Operate – Pre-programmed recipes allow seamless operation for non-experts Explore – Adjust key parameters at detailed levels (e.g., temperature, pH, oxygen) Develop– Access collected data outside of the production cycle to refine and further enhance your individual process TCB announced earlier this year the start of manufacturing at the company’s Burlington, Ontario plant. With an interdisciplinary team of scientists and engineers, TCB refined the production of its AUXO V from lab scale to industrial scale. The multi-use bioreactors are cost-effective, flexible and customizable, designed to offer a unique combination of utility and sustainability. They are equipped with multiple sensors and optimized impellers for different organisms, such as avian and mammalian cells, bacteria or yeast. Short delivery times, modular design and a customer-centric control system make the AUXO V bioreactor a huge accelerator, equipped with novel technology for quick adoption in a rapidly changing market environment. About The Cultivated B (TCB) The Cultivated B’s multinational team of scientists develops and applies breakthrough technologies in cellular agriculture, precision fermentation and advanced bioreactor technology to enable scalable commercialization of the cellular-agriculture industry. TCB serves startups, corporations and academic research institutions within the food, pharma, cosmetics and personal care industries. With its pioneering engineering and production capabilities, TCB enables other companies to produce alternative proteins, such as cultivated meat, at industrial scale. The company’s fundamental commitment to minimizing the natural resources used paves the way toward a sustainable future, locally, regionally and globally. TCB’s research and development team is based in Germany, with manufacturing and an innovation hub based in Canada’s Toronto region. For more information, visit https://www.thecultivatedb.com and follow the company on LinkedIn. Contact Details Jenna Beaucage +1 508-340-6851 tcb@rainerco.com Company Website https://www.thecultivatedb.com

November 30, 2023 08:07 AM Eastern Standard Time

Image

News Release

Filament Health announces non-binding agreement for up to US$14 million in financing

Filament Health Corp

Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to announce the signing of a non-binding term sheet for potential funding of up to US$14.4 million. The funding is in collaboration with an affiliate of Helena Partners Inc., a Cayman-Islands-based advisor and investor. The infusion of capital is expected to significantly bolster Filament Health's operations, particularly in advancing its drug development programs. Furthermore, this funding will play a crucial role in facilitating the completion of the Proposed Business Combination with the Jupiter Acquisition Corporation. Notably, it is a strategic step towards achieving the company's goal of listing on the Nasdaq stock exchange. This financial boost demonstrates Filament Health's commitment to driving innovation in the pharmaceutical sector and expanding its presence in the financial markets. Stay tuned for more updates on Filament Health's exciting journey ahead. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 29, 2023 01:57 PM Eastern Standard Time

Video

THE HOLIDAY GIFT SHOP IS NOW OPEN!

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/4vOaYmrzCQs U.S. online holiday spending is expected to surge to more than $220 billion this year. That puts spending up by almost 5% year over year from about $210 billion in 2022. Adobe holiday spending forecast predicts more than half of online spending will be made via mobile devices. Industry analysts predict electronics, toys, and apparel will see the highest demand and discounts now through December 31 st. Cyber Week will drive $37 billion in online holiday spending. Overall, most shoppers plan on spending just over $800 on holiday gifts this year, totaling more than $180 billion. Braun-Silva has compiled her 2023 list of family gifting ideas. BIG DEALS & UNIQUE GIFTS: Braun-Silva says the majority of consumers are looking for big deals and Big Lots, one of America’s largest home discount retailers, offers extreme bargains on gifts for everyone on your holiday shopping list. The lifestyle expert admits, “I absolutely love their cozy Broyhill reversible knit throw blanket – a dupe for the popular Barefoot Dreams blanket that is all the rage – it’s the perfect gift for a best friend, parents or even yourself at a fraction of the price.” Big Lots truly carries some of the most unique gift items, including a popcorn maker. It’s perfect for a movie night in. She also says shoppers can find top toy brands and save on gifts for the kiddos, adding, “I love the Barbie Groom ‘n Care Horse playset. It’s 32% less at Big Lots than elsewhere!” Direct links: Biglots.com/gifts Social media handles: Facebook: @ biglots Instagram: @ biglots FOR THE GAMER: For the gamers out there, Braun-Silva says Bluey: The Videogame and PAW Patrol World are two recently released kids video games available now on all consoles and PC. “My two boys absolutely love playing them and as both have couch co-op they can play together, so I would highly recommend this as a Christmas gift this year.” In Bluey: The Videogame, gamers can become immersed in the world of Bluey in this interactive adventure game that faithfully recreates iconic locations from the show. With up to 4 players in couch co-op it's the perfect game for all the family. Everyone’s favorite pups have returned in the open-world adventure game PAW Patrol World. Explore Adventure Bay and beyond with up to 2 players in couch co-op in Outright Game’s biggest PAW Patrol game yet! Direct links: Outright Games Social media handles: Facebook: Outright Games Ltd Instagram: O utright_games X (Twitter): @Outright_Games COZY & WARM: Braun-Silva says the holidays are all about those warm and cozy moments. One of her favorite brands is Bedsure. “It’s a budget-friendly and stylish brand where shoppers can find everything cozy this holiday season, whether inside or outdoors, I love their Wearable Blanket Hoodies— Bedsure’s Sherpa Fleece Tall Wearable Blanket Hoodie, Sherpa Fleece, Shaggy Sherpa and Feather Yarn Poncho.” Available in multiple sizes, colors, materials—and matching family sets—these hooded blankets keep consumers and their loved ones snuggly and warm. The super-soft Bedsure Wearable Blanket Hoodie, with nearly 4,000 ratings, is available at Bedsure’s store on Amazon and 20% off for Black Friday. Direct links: Bedsure Sherpa Fleece Tall Wearable Blanket Hoodie Bedsure Sherpa Fleece Wearable Blanket Hoodie Bedsure Shaggy Sherpa Wearable Blanket Hoodie Bedsure Feather Yarn Poncho Wearable Blanket Hoodie Social media handles: Facebook: https://www.facebook.com/bedsurehome Instagram: https://www.instagram.com/bedsurehome Pinterest: https://www.pinterest.com/bedsurehome/ X (Twitter): https://twitter.com/bedsurehome YouTube: https://www.youtube.com/@bedsurehome STYLE & COMFORT: As a New York City woman, Braun-Silva says, “Style is not lost on me.” Duluth Trading has flannel for the whole family. The brand’s Free Swingin’ Flannel is 100% cotton that’s double-brushed for superior softness and comfort. “They call it ‘Free Swingin’’ for a reason too, due to its Reach Gussets at the underarms and deep shoulder pleats that allow you to stretch, reach, move and swing without any restriction,” adds the lifestyle expert. Duluth’s Free Swingin’ Flannels are offered in over 15 different patterns and colors, so there’s one to match everyone’s personal style. Direct link: https://www.duluthtrading.com/gifts/ Social media handle: Instagram: @DuluthTradingCompany HEALTH & HAPPINESS: Braun-Silva says a truly unique family gift idea is associated with health and happiness! “You probably know 23andMe for its DNA test that reveals where in the world your ancestors came from. What you might not know is that it has provided health reports for years. They’re the only company that offers direct-to-consumer health reports authorized by the FDA.” 23andMe provides personalized and actionable genetic insights on health conditions such as type 2 diabetes, celiac disease, high cholesterol, and many more. “This is health information you may not know without a 23andMe test,” adds Braun-Silva, “It’s the perfect gift for those looking to live their best lives.” Direct link: https://www.23andme.com/dna-health-ancestry/ Social media handles: Facebook: https://www.instagram.com/23andMe/ Instagram: https://www.instagram.com/23andMe/ LinkedIn: https://www.linkedin.com/company/23andme/ Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

November 29, 2023 01:55 PM Eastern Standard Time

Video

News Release

Filament Health receives authorization from Health Canada for Phase 2 clinical trial at UBC

Filament Health Corp

Filament Health CEO Ben Lightburn joined Steve Darling from Proactive to share the news that the company has received approval from Health Canada for a phase 2 clinical trial, which will be conducted at the University of British Columbia. This groundbreaking trial will focus on investigating the effects of PEX010, a botanical psilocybin drug candidate developed by Filament, specifically in the context of treating opioid use disorder (OUD). Lightburn explained that the primary objectives of this phase 2 clinical trial are to assess the safety and feasibility of administering psilocybin as a potential treatment for OUD and to evaluate any significant changes in participants' opioid use. The approval of this trial marks a significant step forward in Filament Health's mission to explore innovative and effective interventions for individuals grappling with OUD. Furthermore, Lightburn emphasized the pressing need for research into novel interventions to support those suffering from opioid use disorder. Research thus far has suggested that psychedelic-assisted therapy, such as that involving psilocybin, holds promise as a potentially groundbreaking approach to address this complex and challenging issue. In summary, Filament Health's approval for a phase 2 clinical trial by Health Canada represents a pivotal moment in their commitment to advancing the field of psychedelic-assisted therapy. By investigating the potential of PEX010 in the treatment of opioid use disorder, the company is contributing to the broader scientific understanding of how psychedelics may offer hope and innovative solutions for individuals facing this critical healthcare challenge. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 29, 2023 01:53 PM Eastern Standard Time

Video

NanoViricides updates progress on Phase 1a/1b clinical trial of antiviral drug candidate NV-387

NanoViricides

NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share exciting updates on their antiviral drug candidate, NV 387. The drug, developed in response to the COVID-19 pandemic, demonstrated exceptional safety in clinical trials, even at the highest dose levels, with no adverse events reported. The unique mechanism of action involves mimicking a cell membrane, encapsulating and blocking the virus. The clinical trials involved both oral tablets and oral gummies, catering to various age groups, including pediatrics. NV 387 exhibited broad-spectrum activity against multiple strains of coronaviruses, showcasing effectiveness 10 times greater than remdesivir in preclinical studies. Beyond COVID-19, the drug also displayed promising results against respiratory syncytial virus (RSV), offering a potential solution for infants and seniors where existing treatments like ribavirin may be contraindicated due to side effects. Dr Diwan highlighted the drug's versatility, suggesting applications against other respiratory viruses and even biodefense-related infections like smallpox. The ongoing clinical trial progress and positive results position NanoViricides at the forefront of antiviral drug development, marking a significant milestone in their journey from preclinical research since 2005 to clinical trials. Contact Details Proactive Investors +1 604-688-8158 na-editorial@proactiveinvestors.com

November 29, 2023 01:32 PM Eastern Standard Time

Video

News Release

Vivos Therapeutics hits major milestone with FDA clearance for treating severe sleep apnea

Vivos Therapeutics

Vivos Therapeutics CEO Kirk Huntsman joined Steve Darling from Proactive to announce a significant milestone for the company with its first-ever 510(k) clearance from the US Food and Drug Administration (FDA). The clearance is for the treatment of severe obstructive sleep apnea (OSA) in adults using Vivos' removable CARE oral appliances. This clearance covers Vivos' CARE appliances, which include the flagship DNA oral appliance, the mRNA oral appliance, and the mmRNA oral appliance. Vivos is now the first company to receive FDA approval and bring to market a clear alternative treatment for patients with severe OSA, offering an alternative to continuous positive airway pressure (CPAP) therapy or surgical neurostimulation implants. This achievement follows closely on the heels of Vivos' previous FDA 510(k) clearance granted just eleven months ago, allowing the company to treat mild-to-moderate OSA with its DNA oral appliance. This recent clearance marks the first time the FDA has ever granted approval for an oral appliance to treat both moderate and severe OSA in adults aged 18 and older, in combination with positive airway pressure and/or myofunctional therapy as needed. Vivos Therapeutics' dedication to advancing innovative treatments for sleep apnea underscores its commitment to improving the quality of life for individuals suffering from this condition. With this latest clearance, the company is positioned to provide an effective and accessible treatment option for a broader range of OSA patients, offering hope for improved sleep and overall well-being. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

November 29, 2023 01:04 PM Eastern Standard Time

Video

Africa CDC and Mastercard Foundation launch phase 2 of the Saving Lives and Livelihoods (SLL) initiative to strengthen Africa’s public health systems

Mastercard Foundation

LUSAKA, ZAMBIA - African Media Agency - 29 November 2023 - The Africa CDC and the Mastercard Foundation have entered a new phase of their partnership on the Saving Lives and Livelihoods initiative in the aftermath of WHO's declaration of the end of COVID-19 pandemic as a public health emergency of international concern. The Saving Lives and Livelihoods initiative, a bold and unprecedented $1.5 billion partnership, was launched in June 2021. This innovative and ground-breaking partnership aimed to purchase COVID-19 vaccines, roll out vaccinations, build the vaccine manufacturing workforce for the continent, and strengthen the Africa CDC to ensure long-term health security for Africa. Unprecedented in scale, speed and inclusion of African organisations, the partnership has contributed to the continent's current vaccination rate of 53 per cent of the target population, up from just 3 per cent at the start of the initiative. The partnership has also trained, equipped, and deployed 38,000 health workers, creating a robust frontline in safeguarding public health locally. It has provided job opportunities for 23,000 individuals and integrated over 600 COVID-19 vaccination centres into healthcare systems. Additionally, this initiative led to the expansion of genomic testing capabilities from seven to 40 laboratories across the continent. The review of Phase 1 of this initiative, among fifteen implementing partners across 29 countries, conducted by Deloitte, indicates that the vast majority of funds disbursed were used effectively and as intended. Likewise, ongoing monitoring by KPMG has confirmed that partners not only showed strength in programmatic results but also improved the institutional capacity for greater sustainability and institutional resilience. "Our Saving Lives and Livelihoods initiative with the Mastercard Foundation has shown the power of respectful and action-oriented partnerships rooted in collaboration, coordination and systems strengthening. The experience and learnings from Phase I will enable us to move with greater speed and scale to deliver with accelerated impact to our member states" said Dr. Jean Kaseya, Director General of the Africa CDC. In its second phase, the partnership will expand its scope and scale, focusing on completing the vaccination of healthcare workers and vulnerable groups, building a robust workforce of community health workers, ensuring pandemic preparedness by bolstering national public health institutions, laboratory capacities, data access and quality, local manufacturing of vaccines, therapeutics and diagnostics, and continuing strengthening of Africa CDC. "While the global pandemic may be declared over, the need to continue investing in our health systems, build our workforce and prepare for future pandemics remains urgent. This partnership will ensure that we have strong health institutions and systems. We aim to enable thousands of young people to build their careers in healthcare and contribute to improving lives in Africa," said Reeta Roy, President, and CEO of the Mastercard Foundation. The Saving Lives and Livelihoods initiative stands out as a testament to the power of African-led health solutions. As it progresses to its next phase, partnerships will continue to play a crucial role in shaping a New Public Health Order for Africa. Africa CDC and the Mastercard Foundation remain committed to improving the health and well-being of all Africans. About the Africa Centres for Disease Control and Prevention (Africa CDC) Africa CDC is a continental autonomous health agency of the African Union established to support public health initiatives of Member States and strengthen the capacity of their public health institutions to detect, prevent, control, and respond quickly and effectively to disease threats. For more information, please visit: http://www.africacdc.org About the Mastercard Foundation The Mastercard Foundation is a registered Canadian charity and one of the largest foundations in the world. It works with visionary organisations to advance education and financial inclusion, enabling young people in Africa and Indigenous youth in Canada to access dignified and fulfilling work. Established in 2006 through the generosity of Mastercard when it became a public company, the Foundation is an independent organisation separate from the company, with offices in Toronto, Kigali, Accra, Nairobi, Kampala, Lagos, Dakar, and Addis Ababa. Its policies, operations, and program decisions are determined by the Foundation's Board of Directors and leadership. For more information on the Foundation, please visit www.mastercardfdn.org. Contact Details Wariko Kabuga-Waita wwaita@mastercardfdn.org

November 29, 2023 12:13 PM Eastern Standard Time

Image

ACD/Labs Announces Automation Software to Fast-track Digitalization and AI-Readiness of R&D Laboratories

ACD/Labs

To support ongoing digital transformation in life sciences and chemistry-driven organizations, ACD/Labs has introduced Spectrus Conduit —the first out-of-the-box, low-code/no-code application that connects, designs, and manages automated dataflows from analytical instruments and other data sources. Spectrus Conduit creates standardized, harmonized digital twins of the R&D laboratory, improves collaboration, and supports downstream AI/ML applications. ACD/Labs also announced the expansion of their browser-based Spectrus JS portfolio to proliferate access to cloud-based analytical data management. At BioIT World Europe, ACD/Labs, an informatics company that develops and commercializes software in support of R&D, today announced new applications that will help organizations: Implement automated, extensible analytical data flows from over 150 natively supported instrument formats (NMR, LC/MS, IR, etc.) and other laboratory data sources for improved collaboration and data aggregation. Apply digital chemical intelligence, spectral prediction, and contextual science-based data assembly to produce digital twins of analyses, reducing time-to-market decisions. Facilitate digital knowledge proliferation and accessibility while assuring FAIR and ALCOA+ principles. Accelerate machine learning and data science utilization by simplifying data engineering. ACD/Labs’ Spectrus Platform has helped organizations address their analytical data accessibility challenges for almost thirty years. Decades-long vendor partnerships equip Spectrus Platform users with technique-agnostic, commercial, off-the-shelf support for all major instrument vendor formats. Spectrus offers organizations technologies to support digital transformation (Dx) initiatives—especially those that account for automated data capture, interpretation, and storage of data, with ACD/Labs’ specialty being instrumental analytical chemistry. Recent Spectrus Platform development efforts have focused on the release of an off-the-shelf, low-code/no-code application for the design and management of workflow automation (Spectrus Conduit). In addition, ACD/Labs has continued migrating the capabilities scientists have relied on for decades to browser-based applications. Software in the Spectrus JS family provides on-demand data processing and the facile distribution of data marshaling and management to improve data accessibility. Vice President of Innovation and Informatics Strategy at ACD/Labs, Andrew Anderson, says, “We want to help organizations control the flow of their own instrument-generated data but with the flexibility to adapt such controls without relying on extensive configuration and customization services. Commercial, off-the-shelf capabilities now provided by the Spectrus Platform empower organizations to automate the marshaling, processing, analysis, and proliferation of datasets emanating from their instrument data sources. The application of Spectrus analysis capabilities results in digitally contextualized experimental datasets—digital twins—all without unnecessary manual intervention. Spectrus Conduit not only supports facile, automated, data-driven decision-making for scientists, it also reduces the cost and effort of data science practices. Automated, cross-technique-enabled data science is a significant challenge for the analytical data space today.” “We are building on our legacy of informatics tools to help better address the needs of the scientific community—now and for the digital future,” Anderson continues. “With the introduction of Conduit for automating analytical and instrument workflows, and by continuing the expansion of our browser based Spectrus JS portfolio, we help alleviate software maintenance and support burden on IT teams. We also ensure that your data is not locked into our environment by providing multiple options for export, including JSON export—a necessity when you want to leverage your data for machine learning or AI projects.” To learn more about Spectrus Conduit, Spectrus JS applications, or the Spectrus Platform, visit ACD/Labs at Booth #13 at BioIT World Europe or www.acdlabs.com. About ACD/Labs ACD/Labs is a leading provider of scientific software for R&D. We help customers in >94 countries around the world assemble digitized analytical, structural, and molecular information for effective decision-making, problem solving, and product lifecycle control. Our enterprise technologies enable automation of molecular characterization and facilitate chemically intelligent knowledge management. ACD/Labs provides worldwide sales and support and brings decades of experience and success helping organizations innovate and create efficiencies in their workflows. For more information, please visit www.acdlabs.com. Follow us on Twitter and LinkedIn. Contact Details ACD/Labs Sanji Bhal +1 416-368-3435 media@acdlabs.com Racepoint Global Allison Matthews +1 617-624-3248 rpgacdlabs@racepointglobal.com Company Website https://www.acdlabs.com/

November 29, 2023 04:00 AM Eastern Standard Time

1 ... 72 73 74 75 76 ... 309